Eli Lilly and Co
Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug
Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer‘s newest bet on obesity is already showing promise. The company last week said it would buy […]
Read More
Stocks making the biggest moves midday: Boeing, Paccar, Intel, Mirion Tech and more
Check out the companies making the biggest moves midday: Paccar — The maker of Peterbilt trucks jumped 5% after President Donald Trump slapped a 25% tariff on imported heavy trucks starting Oct. 1. Boeing – The aircraft maker rallied more than 4% after Turkish Airlines ordered 75 Boeing 787 aircraft and said it completed negotiations […]
Read More
Stocks making the biggest premarket moves: Paccar, Intel, RH, Riot Platforms and more
Check out the companies making the biggest moves in premarket trading: Paccar — The maker of Peterbilt trucks jumped 7% after President Donald Trump said slapped a 25% tariff on imported heavy trucks starting Oct. 1. Intel — The chip company added 4.4%. The Wall Street Journal reported Intel has approached Apple , Taiwan Semiconductor […]
Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]
Read More
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in […]
Read More
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market. Pfizer said it will pay an initial $47.50 a share in […]
Read More
Novo Nordisk shares pop 5% after Wegovy pill trial shows ‘significant’ weight reduction
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk said Wednesday that late-stage trial results […]
Read More
Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk‘s own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. The […]
Read More
Jim Cramer says Eli Lilly’s obesity pill could be more of a ‘lifetime drug’ than shots
Don’t count out Eli Lilly’s oral GLP-1 drug for obesity and diabetes just yet, according to CNBC’s Jim Cramer . That was his takeaway following the latest study involving Lilly’s orforglipron, the experimental pill that has been the subject of Wall Street debate since weight-loss data released in early August came in below investor expectations. […]
Read More
UK has gone from a leader to a laggard in biopharma, Eli Lilly CEO says
U.S. policymakers should take note as biopharmaceutical companies pull back on investments in the U.K., Eli Lilly Chief Executive Officer Dave Ricks said in an interview with CNBC. Lilly recently paused plans to create a biotech incubator called Gateway Labs in the U.K., joining other biopharma companies that have put investments in the country on […]
Read More